Skip to main content

Advertisement

SpringerLink
Log in

Serum ADAM metallopeptidase domain 12 as a promising diagnostic biomarker for breast and liver cancer

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Background

ADAM metallopeptidase domain 12 (ADAM12) is generally upregulated in tissues of various tumors, emerging as a prognostic biomarker. However, the clinical significance of serum ADAM12 in tumors still remains to be fully elucidated. The present study aimed to investigate the expression and prognostic value of serum ADAM12 in tumor patients.

Materials and methods

Serum samples were collected from healthy doners (HDs; n = 87) and patients (n = 238) with a clinical diagnosis of breast, liver, lung, stomach and esophageal (STES) and thyroid cancer. Serum ADAM12 protein and mRNA expression was detected by enzyme-linked immunosorbent assay (ELISA) and reverse transcription polymerase chain reaction (RT-PCR), respectively. Receiver–operator characteristic (ROC) analysis was performed to explored the prognostic value of serum ADAM12 expression.

Results

The expression of serum ADAM12 in breast and liver cancer patients was significantly upregulated compared with HDs. In patients with breast cancer, the levels of serum ADAM12 protein and mRNA were significantly higher in tumor stages than that in HDs (p < 0.05), with AUC value of 0.82. In liver cancer, elevated levels of serum ADAM12 protein were significantly correlated with clinical stage (r = 0.74; p = 6.9e−4) and T stage (r = 0.74, p = 7.6e−4), and attained AUC value of 1. However, the clinical significance of serum ADAM12 expression in lung, STES and thyroid cancer had not been found.

Conclusions

Serum ADAM12 expression showed high degree of tumor heterogeneity, and may be a valuable noninvasive diagnostic and prognostic biomarker for breast and liver cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Availability of data and materials

The datasets analyzed during the current study available from the corresponding author on reasonable request.

Code availability

Not applicable.

References

  1. Cao M, Li H, Sun D, Chen W. Cancer burden of major cancers in China: a need for sustainable actions. Cancer Commun (Lond). 2020;40:205–10.

    Article  Google Scholar 

  2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

    Article  Google Scholar 

  3. Li J, Guan X, Fan Z, Ching L-M, Li Y, Wang X, et al. Non-invasive biomarkers for early detection of breast cancer. Cancers (Basel). 2020;12:E2767.

    Article  Google Scholar 

  4. Zong J, Fan Z, Zhang Y. Serum tumor markers for early diagnosis of primary hepatocellular carcinoma. J Hepatocell Carcinoma. 2020;7:413–22.

    Article  CAS  Google Scholar 

  5. Pan Y, Chen H, Yu J. Biomarkers in hepatocellular carcinoma: current status and future perspectives. Biomedicines. 2020;8:E576.

    Article  Google Scholar 

  6. Nyren-Erickson EK, Jones JM, Srivastava DK, Mallik S. A disintegrin and metalloproteinase-12 (ADAM12): function, roles in disease progression, and clinical implications. Biochim Biophys Acta. 2013;1830:4445–55.

    Article  CAS  Google Scholar 

  7. Duffy MJ, McKiernan E, O’Donovan N, McGowan PM. Role of ADAMs in cancer formation and progression. Clin Cancer Res. 2009;15:1140–4.

    Article  CAS  Google Scholar 

  8. Mendaza S, Ulazia-Garmendia A, Monreal-Santesteban I, Córdoba A, de Azúa YR, Aguiar B, et al. ADAM12 is a potential therapeutic target regulated by hypomethylation in triple-negative breast cancer. Int J Mol Sci. 2020;21:E903.

    Article  Google Scholar 

  9. Mochizuki S, Ao T, Sugiura T, Yonemura K, Shiraishi T, Kajiwara Y, et al. Expression and function of a disintegrin and metalloproteinases in cancer-associated fibroblasts of colorectal cancer. Digestion. 2020;101:18–24.

    Article  CAS  Google Scholar 

  10. Ma X, Wu Z, Zhang J, Shao X, Shen H. Increased ADAM12 Expression Predicts Poor Prognosis in Cervical Cancer Patients before General Anesthesia. Clin Lab. 2021;67(2). https://doi.org/10.7754/Clin.Lab.2020.200611.

  11. Carl-McGrath S, Lendeckel U, Ebert M, Roessner A, Röcken C. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol. 2005;26:17–24.

    CAS  Google Scholar 

  12. Cesarini V, Silvestris DA, Tassinari V, Tomaselli S, Alon S, Eisenberg E, et al. ADAR2/miR-589-3p axis controls glioblastoma cell migration/invasion. Nucleic Acids Res. 2018;46:2045–59.

    Article  CAS  Google Scholar 

  13. Du S, Sun L, Wang Y, Zhu W, Gao J, Pei W, et al. ADAM12 is an independent predictor of poor prognosis in liver cancer. Sci Rep. 2022;12:6634.

    Article  CAS  Google Scholar 

  14. Li Z, Wang Y, Kong L, Yue Z, Ma Y, Chen X. Expression of ADAM12 is regulated by E2F1 in small cell lung cancer. Oncol Rep. 2015;34:3231–7.

    Article  CAS  Google Scholar 

  15. Roy R, Rodig S, Bielenberg D, Zurakowski D, Moses MA. ADAM12 transmembrane and secreted isoforms promote breast tumor growth: a distinct role for ADAM12-S protein in tumor metastasis. J Biol Chem. 2011;286:20758–68.

    Article  CAS  Google Scholar 

  16. Huang Z, Lai H, Liao J, Cai J, Li B, Meng L, et al. Upregulation of ADAM12 is associated with a poor survival and immune cell infiltration in colon adenocarcinoma. Front Oncol. 2021;11: 729230.

    Article  Google Scholar 

  17. Zhu H, Jiang W, Zhu H, Hu J, Tang B, Zhou Z, et al. Elevation of ADAM12 facilitates tumor progression by enhancing metastasis and immune infiltration in gastric cancer. Int J Oncol. 2022;60:51.

    Article  CAS  Google Scholar 

  18. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem. 2004;279:51323–30.

    Article  CAS  Google Scholar 

  19. Shi Z, Xu W, Loechel F, Wewer UM, Murphy LJ. ADAM 12, a disintegrin metalloprotease, interacts with insulin-like growth factor-binding protein-3. J Biol Chem. 2000;275:18574–80.

    Article  CAS  Google Scholar 

  20. Duffy MJ, Mullooly M, O’Donovan N, Sukor S, Crown J, Pierce A, et al. The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? Clin Proteomics. 2011;8:9.

    Article  CAS  Google Scholar 

  21. Shao S, Li Z, Gao W, Yu G, Liu D, Pan F. ADAM-12 as a diagnostic marker for the proliferation, migration and invasion in patients with small cell lung cancer. PLoS ONE. 2014;9: e85936.

    Article  Google Scholar 

  22. Shimura T, Dayde D, Wang H, Okuda Y, Iwasaki H, Ebi M, et al. Novel urinary protein biomarker panel for early diagnosis of gastric cancer. Br J Cancer. 2020;123:1656–64.

    Article  CAS  Google Scholar 

  23. Ten Hoorn S, Waasdorp C, van Oijen MGH, Damhofer H, Trinh A, Zhao L, et al. Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer. BMC Cancer. 2022;22:394.

    Article  Google Scholar 

  24. Veenstra VL, Damhofer H, Waasdorp C, van Rijssen LB, van de Vijver MJ, Dijk F, et al. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Oncogenesis. 2018;7:87.

    Article  CAS  Google Scholar 

  25. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.

    Article  Google Scholar 

  26. Roy R, Dagher A, Zurakowski D, Kulke M, Moses MA. Abstract A53: ADAM12 contributes to the malignant potential of pancreatic cancer and may serve as a non-invasive biomarker for its detection. Can Res. 2016;76:A53.

    Article  Google Scholar 

  27. Bilgin Doğru E, Dizdar Y, Akşit E, Ural F, Şanlı Ö, Yasasever V. EMMPRIN and ADAM12 in prostate cancer: preliminary results of a prospective study. Tumour Biol. 2014;35:11647–53.

    Article  Google Scholar 

  28. Cheon D-J, Li AJ, Beach JA, Walts AE, Tran H, Lester J, et al. ADAM12 is a prognostic factor associated with an aggressive molecular subtype of high-grade serous ovarian carcinoma. Carcinogenesis. 2015;36:739–47.

    Article  CAS  Google Scholar 

  29. Wang R, Godet I, Yang Y, Salman S, Lu H, Lyu Y, et al. Hypoxia-inducible factor-dependent ADAM12 expression mediates breast cancer invasion and metastasis. Proc Natl Acad Sci U S A. 2021;118: e2020490118.

    Article  CAS  Google Scholar 

  30. Gao J, Yang D, Xu H, Yang K, Ma J, Xia J, et al. ADAM metallopeptidase domain 12 overexpression correlates with prognosis and immune cell infiltration in clear cell renal cell carcinoma. Bioengineered. 2022;13:2412–29.

    Article  CAS  Google Scholar 

  31. Nyren-Erickson EK, Bouton M, Raval M, Totzauer J, Mallik S, Alberto N. Urinary concentrations of ADAM 12 from breast cancer patients pre- and post-surgery vs. cancer-free controls: a clinical study for biomarker validation. J Negat Results Biomed. 2014;13(1):1–8.

    Article  Google Scholar 

  32. Zuo Z, Hu H, Xu Q, Luo X, Peng D, Zhu K, et al. BBCancer: an expression atlas of blood-based biomarkers in the early diagnosis of cancers. Nucleic Acids Res. 2020;48:D789–96.

    CAS  Google Scholar 

Download references

Acknowledgements

The authors wish to thank all patients, healthy donors and staff of our hospital that participated in this study.

Funding

This work was supported by the National Natural Science Foundation of China (No. 82073284); Guangdong Basic and Applied Basic Research Foundation (No. 2021A1515012163); Shenzhen Key Medical Discipline Construction Fund (No. SZXK053).

Author information

Author notes

  1. Hanchu Wang, Huan Wu contributed equally to this work.

Authors and Affiliations

  1. Department of Medical Laboratory, The Second Clinical Medical College, Jinan University (Shenzhen People’s Hospital), Shenzhen, 518020, China

    Hanchu Wang, Huan Wu & Yue Chen

  2. Integrated Chinese and Western Medicine Postdoctoral Research Station, Jinan University, Guangzhou, 510632, China

    Huan Wu

Authors
  1. Hanchu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Huan Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yue Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YC, HWang and HWu designed and performed the study, and wrote the manuscript; HWang performed sample collection and the experiments; HWang and HWu analyzed the data. All authors contributed to the article and approved the submitted version.

Corresponding author

Correspondence to Yue Chen.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interest.

Ethical approval

The studies involving human participants were reviewed and approved by the Medical Ethics Committee of the second clinical medical collage of Jinan University (Shenzhen People’s Hospital) (certification no. LL-KY-20200414).

Consent to participate

All participants approved to participate in this study.

Consent for publication

All of the co-authors consented to publish this manuscript. A copy of the written consent is available for review.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 46 KB)

Supplementary file2 (DOCX 466 KB)

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, H., Wu, H. & Chen, Y. Serum ADAM metallopeptidase domain 12 as a promising diagnostic biomarker for breast and liver cancer. Clin Transl Oncol 25, 473–481 (2023). https://doi.org/10.1007/s12094-022-02960-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-022-02960-2

Keywords

Search

Navigation